Article
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.
Clinical pharmacokinetics - 1 Jun 2017
Tout Mira, Gagez Anne-Laure, Leprêtre Stéphane, Gouilleux-Gruart Valérie, Azzopardi Nicolas, Delmer Alain, Mercier Mélanie, Ysebaert Loïc, Laribi Kamel, Gonzalez Hugo, Paintaud Gilles, Cartron Guillaume, Ternant David
Abstract excerpt
BACKGROUND AND OBJECTIVES: Rituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Rituximab pharmacokinetics shows a time dependency possibly related to changes in the target antigen amount over time. The purpose of this study was to quantify the influence of both CD20 antigenic mass and the FcγRIIIA genetic polymorphism on rituximab...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.